Narcolepsy is caused by a selective loss of hypocretin neurons and is associated with obesity. Ghrelin and leptin interact with hypocretin neurons to influence energy homeostasis. Here, we evaluated whether human hypocretin deficiency, or the narcolepsy therapeutic agent sodium oxybate (SXB), alter the levels of these hormones.
IntroductIon
The hypocretin system, also known as the orexin system, is of major importance in the regulation of sleep and sustained wakefulness. Moreover, hypocretin neurons are responsive to metabolites and hormones helping to translate signals of metabolic state into adaptive levels of activity and consciousness. 156;157 Hypocretin deficiency leads to narcolepsy, a sleepwake disorder characterized by excessive daytime sleepiness, cataplexy, and disrupted nocturnal sleep. Obesity is associated with the disorder, 18 yet the cause of the increased body weight has been challenging to discern due to inconsistent findings on the hormonal and metabolic characteristics of this population. 22;30;31;33;81;151 However, altered ingestive behavior has been observed in these patients, 81;158-160 suggesting hypocretin deficiency may dysregulate feeding behavior, and possibly energy homeostasis.
Ghrelin is a peptide hormone mainly produced by endocrine cells in the stomach and gastrointestinal tract, and is an important endogenous regulator of energy balance and growth hormone (GH) secretion. 161 Its expression is complex89 and influenced by sympathetic nervous system activity. 90 Across the wake period, plasma concentrations wax and wane episodically, providing an appetite-stimulating signal to the brain. 91 During sleep, ghrelin levels rise sharply in the early part of the night and decrease gradually toward morning. During sleep deprivation, however, levels gradually rise toward a plateau in the morning. 162 Hypocretin neurons directly sense and are excited by ghrelin, and an interaction between these two systems has been shown to be involved in ingestive behavior. 87 A study by Toshinai et al. first identified this connection. 92 In that study, ghrelin-induced feeding was attenuated in rats pretreated with anti-hypocretin-1 IgG and anti-hypocretin-2 IgG, and suppressed in hypocretin knockout mice.
Later, it was demonstrated that ghrelin plays a key role in the rewarding aspects of eating, but it requires the presence of intact hypocretin signaling to impart this effect.
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Leptin is another peptide hormone involved in energy homeostasis, the dominant role of which is to signal energy deficiency to the brain. 164 It is an adipokine produced primarily by subcutaneous white adipose tissue, and its expression is stimulated by various hormones, sympathetic outflow, energy intake, and output. total ghrelin or leptin are uni-or bi-directional. Because hypocretin influences sympathetic outflow and sympathetic nervous system activity affects the expression of both leptin and ghrelin, hypocretin deficiency may lead to altered levels of these hormones. This study of hypocretin deficient narcoleptic patients provides a unique opportunity to further explore the nature of these relationships. We hypothesized that both total ghrelin and leptin levels would be abnormal in hypocretin-deficient narcolepsy patients, which might help explain the increased BMI and abnormal ingestive behavior seen in this population. 22;30;81;149;170;171 Additionally, we explored if the narcolepsy therapeutic agent, sodium oxybate (SXB), has an effect on these hormones. In a narcolepsy population, SXB improves disrupted nocturnal sleep, impaired wakefulness, and cataplexy, and promotes weight loss. 74;172 Like ghrelin, SXB administration also stimulates GH release. 75 We hypothesized that its administration would alter total ghrelin levels, the effect of which might be involved in its GH-promoting effects.
Here, we investigate whether total blood ghrelin or leptin levels are altered in hypocretindeficient narcoleptic patients compared to controls, and whether total ghrelin or leptin levels are influenced by SXB. Two patients were drug naive, one patient was tapered from antidepressants ≥ 2 weeks prior to the study, and 2 patients had prior history with SXB; however, no subject took sodium oxybate within 20 days of study initiation. The other patients did not take any medication for at least several months prior to beginning the study.
MAterIAls And Methods
Subjects were eligible for participation after exclusion of chronic conditions, with particular attention to the absence of sleep disorders in control subjects, hypertension, pituitary disease, and weight change (> 3 kg weight gain or loss within the last 3 months) as assessed by structured clinical interview. None of the participants had previously undergone gastrectomy.
Written informed consent was obtained from all subjects. The study was approved by the ethics committee of the Leiden University Medical Center.
clinical protocol
All subjects were admitted to the Clinical Research Center for 24-h blood sampling before and after 5 days of SXB administration. A cannula was inserted into an antecubital vein ≥ 45 min before the start of blood sampling at 12:00. Blood samples were collected with S-Monovette (Sarstedt, Etten-Leur, The Netherlands) from a 3-way stopcock that was attached to a 0.9% NaCl and heparin (1 U/mL) infusion (750 mL/24 h) to keep the cannula from clotting. For total ghrelin measurements, blood was collected in EDTA tubes at 60-min intervals, and these tubes were immediately put on ice. Ghrelin samples were acidified with 50 μL of 1 N HCL. Within 5 min of sampling, tubes were centrifuged at 1,250 g at 4°C for 20 minutes.
For leptin measurements, blood was collected at 20-min intervals. After clotting, the blood was centrifuged within 30 min of sampling (20 min, 1,250 g, 4°C). Serum was then stored at -80°C until hormonal assays. Three standardized meals were served at 08:30, 13:00, and 18:00 (Nutridrink, 1.5 kcal/mL, 2,100 kcal/d; macronutrient composition per 100 mL: protein, 6 g; fat, 5.8 g; carbohydrate, 18.4 g; Nutricia, Zoetermeer, The Netherlands). Subjects were asked to complete each meal provided. Food-induced suppression of total ghrelin release was defined as the ratio between total ghrelin levels one hour post-prandially to the levels immediately before the meal (lunch and dinner) or 30 min postprandially to 30 min before the meal (breakfast). Subjects remained sedentary except for bathroom visits. In both study occasions, lights were switched off (dark period) at 23:00 and then switched on at 07:30.
sodium oxybate
In the drug-intervention study occasion, SXB was administered in a total nightly dose of 6 grams/night for 5 consecutive nights in both the narcoleptic patients and the controls. Each night, 3 grams of SXB were administered orally at 23:00 and 03:00. Lights were turned off after ingestion of the first dose.
Assays
Plasma total ghrelin and leptin levels were measured by radioimmunoassay (LINCO Research, St. Charles, MO, USA) with a detection limit of 93 pg/mL, and an interassay variation ranging from 14.7% to 17.8% for total ghrelin and a detection limit of 0.5 μg/L and an interassay variation ranging from 3.0% to 5.1% for leptin. Samples from each patient and matched control were handled in the same run.
Deconvolution analysis
Leptin concentration time series were analyzed via a recently developed automated deconvolution method, empirically validated using hypothalamo-pituitary sampling and 
Data analysis and statistics
Results are expressed as mean ± SD unless otherwise specified. Unpaired t-tests were used to assess differences in means between the 2 groups, while paired t-tests were applied to assess changes in means within each group. All tests were 2-tailed, and significance level was set at P < 0.05. Statistical analyses were performed using SPSS for Windows (release 17.0, SPSS, Inc., Chicago, IL).
results subjects
Patients and controls did not differ with respect to age, BMI, waist-to-hip ratio, and body fat percentage (Table 4 .1). SXB was well tolerated by all participants. Apart from mild drowsiness, no other side effects were reported during the study.
Sleep and wakefulness differences
When compared to controls, during baseline conditions and after SXB administration, narcolepsy patients spent significantly less time awake across a 24 h period, and during the day (defined as the lights-on period between 07:30-23:00) they spent less time awake and more time in slow wave sleep ([SWS] P = 0.004 and P = 0.005, respectively; Table 4 .2).
Effect of sodium oxybate administration on sleep and wakefulness
In both groups, administration of SXB resulted in a significant decrease in stages I/II NREM and REM sleep over 24 h (P = 0.011 and P = 0.009, respectively), while at night, awakenings were significantly reduced (P = 0.002) and the percentage of SWS more than doubled (narcolepsy: 6.5% ± 5.5% vs.16.5% ± 8.4%, controls: 7.1% ± 5.5% vs. 18.5% ± 6.4%; P = 0.001 for administration effect). During the day, time spent in stages I/II NREM and REM sleep (P = 0.038 and P = 0.041, respectively) was reduced, while there was a trend towards longer periods of wakefulness (P = 0.098). Data are shown as mean ± SEM. Percentages of sleep stages during the 24 h of study, before and after SXB administration. Unpaired t-tests were used to assess differences between the 2 groups. Mixed-effects models were applied to assess the effect of treatment and potential interaction effects between group (i.e. narcolepsy or control) and treatment. * p < 0.05 and ** p < 0.01.
baseline total ghrelin levels
Mean 24-h total ghrelin levels at baseline were virtually identical between narcolepsy patients and controls (P = 0.873; Figure 4 .1A). Mean total ghrelin levels were also not different between the 2 groups when the analyses were restricted to the dark period (P = 0.973).
In fact, at no single time-point an intergroup difference could be detected (all P ≥ 0.232).
Food induced suppression of total ghrelin concentration (expressed as the ratio between postprandial to preprandial total ghrelin concentration) was similar in the 2 groups (lunch: P = 0.413, dinner: P = 0.301, breakfast: P = 0.437, and mean postprandial total ghrelin levels averaged over the 3 occasions [P = 0.540]) (Table 4. 3).
Effect of sodium oxybate on total ghrelin levels
Twenty-four hour mean total ghrelin levels during SXB administration were not different between narcolepsy patients and controls (P = 0.642; Figure 4 .1B). Similar to baseline, mean and at no single time-point a difference could be detected between groups (all P ≥ 0.05).
Postprandial total ghrelin suppression, as defined above, was also similar between the 2 groups after SXB administration: lunch (P = 0.920), dinner (P = 0.261), and breakfast (P = 0.880); mean postprandial total ghrelin levels averaged over the 3 occasions (P = 0.428) (Table 4. 3). The average change in 24-h total ghrelin levels between the second and first occasion amounted to -15 ± 72 pg/mL in narcolepsy patients and -63 ± 87 pg/mL in controls, but was not significantly different from zero in either group (paired t-tests: P = 0.56 and P = 0.078, respectively). 
Baseline leptin levels
Mean 24-h total leptin levels at baseline were not significantly different between narcolepsy patients and controls (P = 0.18; Figure 4 .2A). Mean pulse frequency was different between the 2 groups (P = 0.04), but mean 24-h basal and pulsatile secretion levels were not different (P = 0.96; P = 0.11, respectively; Table 4 .3). 
Effect of sodium oxybate on leptin levels
Mean 24-h total leptin levels during SXB treatment were not significantly different between narcolepsy patients and controls (P = 0.58; Figure 4 .2B); neither were mean 24-h basal and pulsatile secretion rates (P = 0.94; P = 0.29, respectively). Mean pulse frequency was different between the 2 groups (P = 0.04; Table 4 .3).
dIscussIon
We found no differences in mean 24-h total plasma ghrelin levels or food-induced suppression of ghrelin concentrations between narcolepsy patients and controls, nor any influence of 5 days of SXB administration in both groups. In view of the capacity of ghrelin to stimulate growth hormone secretion, it is worth noting that a report from this same research protocol showed no differences in mean hourly GH levels between patients and controls, supporting our conclusion that total ghrelin levels are not altered with hypocretin deficiency.
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Despite the excitatory influence of ghrelin on hypocretin neurons and the interaction of the ghrelin-hypocretin systems to influence food reinforcement, our finding did not show the total ghrelin level to be influenced by hypocretin deficiency, suggesting a unidirectional relationship. These findings also suggest that disturbed ingestive behavior is unlikely mediated by an altered total ghrelin level in narcolepsy patients. Notably, we measured total ghrelin levels and not the biologically active, octanoylated-ghrelin fraction. While there is a high correlation between the total and octanoylated fraction ghrelin level, 174 it remains possible that the active fraction may be altered in this population. we did not find alterations in total ghrelin and leptin concentrations in this controlled and standardized environment, it remains possible that the release of these hormones is affected by the altered sleep, wake, and eating patterns described in this population.
As expected, in both groups nighttime administration of SXB increased SWS and reduced awakenings, and the narcoleptic patient group showed a trend towards increased wakefulness the following day. As demonstrated in other studies, acute SXB administration corresponds with a significant increase in GH release. 75;173 However, we found no evidence that the GHelevating effect is mediated through an influence on total ghrelin secretion. Various treatment effects of SXB exhibit discrete temporal dynamics with some effects occurring acutely and other effects taking place only after chronic exposure. Although the difference in total ghrelin levels between patients and controls after SXB administration was not significant, it is possible that significant differences would be seen with higher doses, prolonged periods of nightly administration, or in a larger group of subjects. Lastly, we did not see an effect of SXB on the leptin level, and to our knowledge, an interaction between this drug and hormone has not been reported elsewhere. Therefore, mechanisms underlying increased BMI and altered ingestive behavior in narcolepsy and the effects of SXB administration on GH release and weight loss are unlikely to involve changes in total plasma ghrelin or leptin concentrations. Future investigations should further evaluate if the sleep-wake instability intrinsic to hypocretin deficient narcolepsy promotes ingestive and activity patterns that promote positive energy balance.
